8,374
Participants
Start Date
April 30, 2014
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
HEPLISAV
Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
Engerix-B
Intramuscular injections at Week 0, Week 4, and Week 24
Clinical Research Advantage, Inc., Anderson
Radiant Research, Anderson
Radiant Research, Greer
Radiant Research, Atlanta
Radiant Research, Pinellas Park
Clinical Research Advantage, Inc., Birmingham
Radiant Research, Columbus
Radiant Research, Akron
Radiant Research, Cincinnati
Clinical Research Advantage, Inc, Evansville
Clinical Research Advantage, Inc., Council Bluffs
Radiant Research, Edina
Radiant Research, Chicago
Clinical Research Advantage, Inc., Elkhorn
Clinical Research Advantage, Inc., Fremont
Clinical Research Advantage, Inc., Omaha
Clinical Research Advantage, Inc., Plano
Radiant Research, Dallas
Radiant Research, San Antonio
Clinical Research Advantage, Inc., Centennial
Radiant Research, Denver
Clinical Research Advantage, Inc., Colorado Springs
Radiant Research, St Louis
Radiant Research, Murray
Clinical Research Advantage, Inc., Phoenix
Clinical Research Advantage, Inc., Phoenix
Clinical Research Advantage, Inc., Phoenix
Clinical Research Advantage, Inc., Mesa
Clinical Research Advantage, Inc., Mesa
Clinical Research Advantage, Inc., Chandler
Radiant Research, Chandler
Radiant Research, Scottsdale
Clinical Research Advantage, Inc., Tempe
Clinical Research Advantage, Inc., Glendale
Radiant Research, Tucson
Clinical Research Advantage, Inc., Tucson
Clinical Research Advantage, Inc., Henderson
Clinical Research Advantage, Inc., Las Vegas
Clinical Research Advantage, Inc., Vista
Radiant Research, Santa Rosa
Lead Sponsor
Dynavax Technologies Corporation
INDUSTRY